Interrupting the PD-1 signaling pathway that activates tumor-infiltrating ILC2s can promote antitumor effects, and a combination of IL-33 treatment and anti-PD-1 therapy may maximally expand ILC2s and promote their function. Here, IL33 is linked to neoplasm.